Table IV.
Superior capsular reconstruction graft failure rates
| Author (Year) | Graft Type | N | n with Post-Op MRI | Timing of Imaging (years) | Graft Failure Rate |
|---|---|---|---|---|---|
| Hirihara (2017) | HDA | 8 | 5 | 2 | 1/5 (20%) |
| Denard (2018) | HDA | 59 | 20 | 1 | 11/20 (55%) |
| Pennington (2018) | HDA | 88 | 4 | 2 | 3/4 (75%) |
| Burkhart (2019) | HDA | 10 | 10 | 1 | 3/10 (30%) |
| Woodmass (2019) | HDA | 34 | Not Reported | Not Reported | 22/34 (65%)* |
| Burkhart (2020) | HDA | 41 | 26 | 1 | 4/26 (15%) |
| Lacheta (2020) | HDA | 22 | 21 | 0.2 | 9/21 (43%) |
| HDA Total | 262 | 86 | 32/86 (37%) | ||
| Mihata (2013) | TFL | 24 | 24 | 3 | 4/24 (17%) |
| De Campos Azevedo (2018) | TFL | 22 | 22 | 0.5 | 2/22 (9%) |
| Lee (2018) | TFL | 36 | 36 | 1 | 13/36 (36%) |
| Lim (2018) | TFL | 31 | 31 | 1 | 9/31 (29%) |
| Mihata (2018) | TFL | 88 | 88 | 5 | 4/88 (5%) |
| Mihata (2019) | TFL | 30 | 30 | 2.5 | 3/30 (10%) |
| TFL Total | 231 | 231 | 35/231 (15%) |
SCR: Superior Capsule Reconstruction
HDA: Human Dermal Allograft
TFL: Tensor Fascia Lata Autograft
N=Total number of patients
*
Graft failure rate determined by clinical examination rather than advanced imaging